Zoetis Inc. (NYSE:ZTS) Shares Sold by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. cut its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 27.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,848 shares of the company's stock after selling 3,016 shares during the quarter. First Citizens Bank & Trust Co.'s holdings in Zoetis were worth $1,292,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC raised its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the period. Navigoe LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $30,000. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the fourth quarter valued at $44,000. Finally, Asset Planning Inc purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $58,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS traded up $2.49 during trading hours on Tuesday, reaching $167.10. The stock had a trading volume of 2,741,141 shares, compared to its average volume of 2,544,871. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market cap of $74.39 billion, a P/E ratio of 30.55, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The stock has a fifty day moving average of $157.43 and a 200 day moving average of $164.12.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the business earned $1.38 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis's dividend payout ratio is presently 35.91%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ZTS shares. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $212.75.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.18% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.